+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Telmisartan Market By Indication (Hypertension and Cardiovascular Risk Reduction), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies), By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026

  • ID: 5314868
  • Report
  • March 2021
  • Region: Asia Pacific
  • 72 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Abbott Laboratories
  • Aurobindo Pharma Limited
  • Cipla Limited
  • GlaxoSmithKline PLC (GSK)
  • Mylan N.V.
  • Sanofi S.A.
The Asia Pacific Telmisartan Market is expected to witness market growth of 7.2% CAGR during the forecast period (2020-2026).

Telmisartan is considered as a prescription medication, which is frequently suggested to ease down and broaden blood vessels in persons having elevated blood pressure. Telmisartan means a set of drugs called as angiotensin II receptor blockers (ARBs). Telmisartan could be utilized alone or in combination with other medications like hydrochlorothiazide with an aim to treat elevated blood pressure.

The growth of the Telmisartan market is expected to be supplemented by the increasing number of supportive government policies for hypertension management. For example, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) introduced, ‘India Hypertension Management Initiative (IHMI)’. The IHMI focuses to decrease death & disability associated with cardiovascular disease (CVD), by enhancing control over elevated blood pressure (hypertension), lowering down salt consumption from food, and cutting down artificial trans-fats, which are supporting the risks for creating CVD.

The Hypertension market dominated the Malaysia Telmisartan Market by Indication in 2019, thereby, achieving a market value of $45.1 million by 2026. The Cardiovascular Risk Reduction market is expected to witness a CAGR of 9% during (2020 - 2026).

Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).

Scope of the Study

Market Segments covered in the Report:

By Indication
  • Hypertension
  • Cardiovascular Risk Reduction
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
By Country
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
Companies Profiled
  • Abbott Laboratories
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • GlaxoSmithKline PLC (GSK)
  • Mylan N.V.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Aurobindo Pharma Limited
  • Cipla Limited
  • GlaxoSmithKline PLC (GSK)
  • Mylan N.V.
  • Sanofi S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Telmisartan Market, by Indication
1.4.2 Asia Pacific Telmisartan Market, by Distribution Channel
1.4.3 Asia Pacific Telmisartan Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Asia Pacific Telmisartan Market by Indication
3.1 Asia Pacific Hypertension Market by Country
3.2 Asia Pacific Cardiovascular Risk Reduction Market by Country

Chapter 4. Asia Pacific Telmisartan Market by Distribution Channel
4.1 Asia Pacific Hospital Pharmacies Market by Country
4.2 Asia Pacific Drug Stores and Retail Pharmacies Market by Country
4.3 Asia Pacific Online Pharmacies Market by Country

Chapter 5. Asia Pacific Telmisartan Market by Country
5.1 China Telmisartan Market
5.1.1 China Telmisartan Market by Indication
5.1.2 China Telmisartan Market by Distribution Channel
5.2 India Telmisartan Market
5.2.1 India Telmisartan Market by Indication
5.2.2 India Telmisartan Market by Distribution Channel
5.3 Japan Telmisartan Market
5.3.1 Japan Telmisartan Market by Indication
5.3.2 Japan Telmisartan Market by Distribution Channel
5.4 South Korea Telmisartan Market
5.4.1 South Korea Telmisartan Market by Indication
5.4.2 South Korea Telmisartan Market by Distribution Channel
5.5 Malaysia Telmisartan Market
5.5.1 Malaysia Telmisartan Market by Indication
5.5.2 Malaysia Telmisartan Market by Distribution Channel
5.6 Malaysia Telmisartan Market
5.6.1 Malaysia Telmisartan Market by Indication
5.6.2 Malaysia Telmisartan Market by Distribution Channel
5.7 Rest of Asia Pacific Telmisartan Market
5.7.1 Rest of Asia Pacific Telmisartan Market by Indication
5.7.2 Rest of Asia Pacific Telmisartan Market by Distribution Channel

Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Aurobindo Pharma Limited
6.2.1 Company Overview
6.2.1 Financial Analysis
6.2.2 Regional Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments
6.2.4.1 Approvals
6.2.4.2 Acquisition and Mergers
6.3 Boehringer Ingelheim International GmbH
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments
6.3.5.1 Approvals
6.3.5.2 Partnerships, Collaborations, and Agreements
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments
6.4.5.1 Partnerships, Collaborations, and Agreements
6.4.5.2 Approvals
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Mylan N.V.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments
6.6.5.1 Product Launches and Product Expansions
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Sun Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments
6.8.5.1 Approvals
6.8.5.2 Product Launches and Product Expansions
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments
6.9.5.1 Approvals
6.9.5.2 Product Launches and Product Expansions
6.10. Cadila Healthcare Ltd. (Zydus Cadila)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments
6.10.5.1 Approvals
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • GlaxoSmithKline PLC (GSK)
  • Mylan N.V.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll